Atul Deodhar
Overview
Explore the profile of Atul Deodhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
246
Citations
5698
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van den Bosch F, Deodhar A, Poddubnyy D, Maksymowych W, van der Heijde D, Kim T, et al.
Arthritis Res Ther
. 2025 Feb;
27(1):23.
PMID: 39905436
Background: In SELECT-AXIS 2, upadacitinib improved the signs and symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) through 52 weeks versus placebo and was well tolerated. Here, we evaluated the efficacy...
2.
Deodhar A, Navarro-Compan V, Poddubnyy D, Gensler L, Ramiro S, Tomita T, et al.
RMD Open
. 2025 Jan;
11(1).
PMID: 39890205
Objective: Assess long-term safety, tolerability and efficacy of bimekizumab in ankylosing spondylitis (radiographic axial spondyloarthritis (r-axSpA)). Methods: Patients with active r-axSpA completing the dose-ranging 48-week randomised controlled trial could enrol...
3.
Lebwohl M, Deodhar A, Schwartzman S, Salvarani C, Feely McDonald M, Bello N, et al.
Dermatol Ther (Heidelb)
. 2025 Jan;
15(1):161-188.
PMID: 39843709
Introduction: Psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) may confer an increased risk for cardiovascular (CV) disease, including major adverse cerebro-cardiovascular events (MACE), deep vein thrombosis (DVT), and...
4.
Baraliakos X, Deodhar A, van der Heijde D, Van den Bosch F, Magrey M, Maksymowych W, et al.
Rheumatology (Oxford)
. 2025 Jan;
PMID: 39798135
Objectives: Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1 year in patients with non-radiographic (nr-)...
5.
Deodhar A, Akar S, Curtis J, El-Zorkany B, Magrey M, Wang C, et al.
Adv Rheumatol
. 2024 Dec;
64(1):87.
PMID: 39695887
Objectives: Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS). Method: Pooled data from Phase 2 (NCT01786668; 04/2013-03/2015)/Phase 3 (NCT03502616; 06/2018-08/2020)...
6.
Bittar M, Deodhar A
JAMA
. 2024 Dec;
333(5):408-420.
PMID: 39630439
Importance: Axial spondyloarthritis is an immune-mediated inflammatory condition involving the sacroiliac joints, spine, and peripheral joints. It affects approximately 1% of adults in the US and is associated with impaired...
7.
Baraliakos X, van der Heijde D, Sieper J, Inman R, Kameda H, Maksymowych W, et al.
Arthritis Res Ther
. 2024 Nov;
26(1):197.
PMID: 39533349
Background: The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR) were evaluated through 1 year in the SELECT-AXIS...
8.
Navarro-Compan V, Rudwaleit M, Dubreuil M, Magrey M, Marzo-Ortega H, Mease P, et al.
J Rheumatol
. 2024 Oct;
52(1):23-32.
PMID: 39406403
Objective: To assess the effect of bimekizumab on pain, morning stiffness, and fatigue in patients with nonradiographic and radiographic axial spondyloarthritis (axSpA) in the phase III BE MOBILE studies (ClinicalTrials.gov:...
9.
Danve A, Magrey M, Deodhar A
BMC Sports Sci Med Rehabil
. 2024 Oct;
16(1):211.
PMID: 39375817
Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which mainly affects the spine and sacroiliac joints, causing longstanding back pain, stiffness, and limited mobility. AxSpA is an underrecognized disease...
10.
Mease P, Baraliakos X, Chandran V, Soriano E, Nash P, Deodhar A, et al.
ACR Open Rheumatol
. 2024 Oct;
6(12):880-890.
PMID: 39365294
Objective: Group-level analyses from the phase 3 DISCOVER-2 trial of guselkumab demonstrated robust and durable improvements across psoriatic arthritis (PsA) domains. To specifically evaluate continuous disease control in individual patients,...